Search Results - "Diodato, E."

Presenilin-1 Regulates the Neuronal Threshold to Excitotoxicity Both Physiologically and Pathologically by Grilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M., Uberti, D., Rozmahel, R., Westaway, D., St George-Hyslop, P., Memo, M., Ongini, E.

“…A direct pathophysiological role of Familial Alzheimer's Disease (FAD)-associated Presenilin 1 (PS1) mutations in neuronal vulnerability remains a…”
Get full text

An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease by Süssmuth, Sigurd D., Haider, Salman, Landwehrmeyer, G. Bernhard, Farmer, Ruth, Frost, Chris, Tripepi, Giovanna, Andersen, Claus A., Di Bacco, Marco, Lamanna, Claudia, Diodato, Enrica, Massai, Luisa, Diamanti, Daniela, Mori, Elisa, Magnoni, Letizia, Dreyhaupt, Jens, Schiefele, Karin, Craufurd, David, Saft, Carsten, Rudzinska, Monika, Ryglewicz, Danuta, Orth, Michael, Brzozy, Sebastian, Baran, Anna, Pollio, Giuseppe, Andre, Ralph, Tabrizi, Sarah J., Darpo, Borje, Westerberg, Goran

“…Aims Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease‐modifying therapeutic for Huntington's disease (HD). This was the…”
Get full text

Promoting Tourism Education in MENA Countries: Geopolitical Implications by Emidio Diodato

“…Tourism development across the Middle East and North Africa is mostly based on low cost and mass beach leisure. This kind of tourism development generated,…”
Get full text

F02 Selisistat: soluble HTT protein levels as a potential pharmacodynamic readout by Westerberg, G, Massai, L, Magnoni, L, Pollio, G, Tripepi, G, Diodato, E, Caricasole, A, Bernocco, S, Tabrizi, SJ, Landwehrmeyer, B

“…BackgroundSiena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat is a potent and selective SirT1…”
Get full text

F02Selisistat: soluble HTT protein levels as a potential pharmacodynamic readout by Westerberg, G, Massai, L, Magnoni, L, Pollio, G, Tripepi, G, Diodato, E, Caricasole, A, Bernocco, S, Tabrizi, S J, Landwehrmeyer, B

“…BackgroundSiena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat is a potent and selective SirT1…”
Get full text

Detection of phosphorylation patterns in rat cortical neurons by combining phosphatase treatment and DIGE technology by Raggiaschi, Roberto, Lorenzetto, Chiara, Diodato, Enrica, Caricasole, Andrea, Gotta, Stefano, Terstappen, Georg C.

“…Although protein phosphorylation is probably the most studied post‐translational modification occurring in cells, the number of proteins, which are the target…”
Get full text

Ecdysone-based system for controlled inducible expression of metabotropic glutamate receptor subtypes 2, 5, and 8 by Downey, Patrick M, Lozza, Gianluca, Petrò, Roberta, Diodato, Enrica, Foglia, Chiara, Bottazzoli, Federica, Brusa, Rossella, Asquini, Tatiana, Reggiani, Angelo, Grilli, Mariagrazia

“…Stable and inducible expression of human metabotropic glutamate receptor types 2, 5, and 8 was achieved in HEK293 cells using the ecdysone inducible system…”
Get more information